Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Metformin Accumulation and Renal Impairment

Clinical Consequences and Prevention

  • The Kidney International guidelines recommend that for patients with eGFR 30-44 mL/min/1.73 m², metformin dose should be reduced to 1000 mg daily to prevent accumulation while maintaining therapeutic benefit 2, 3
  • Metformin is contraindicated in patients with eGFR <30 mL/min/1.73 m² because the risk of accumulation and lactic acidosis becomes unacceptably high 2
  • For patients with eGFR 45-59 mL/min/1.73 m², dose reduction should be considered if other risk factors for lactic acidosis are present, such as heart failure, liver disease, or alcoholism 2
  • The Kidney International guidelines also recommend that eGFR should be monitored at least annually in all patients taking metformin, with increased frequency (every 3-6 months) once eGFR falls below 60 mL/min/1.73 m² 2, 4
  • Using serum creatinine alone rather than eGFR to guide metformin dosing can lead to inappropriate continuation in patients with reduced muscle mass, making eGFR a more reliable measure for dosing adjustments 4